Polynucleotides
Polynucleotides for facial redness: what does the evidence actually show?
Facial redness has many possible causes. A two-patient report suggests that a combined polynucleotide and hyaluronic acid injectable deserves further study, but it does not establish a treatment for rosacea or persistent erythema.
Redness is a sign, not a diagnosis
Facial redness may be temporary flushing or persistent erythema. Possible causes include rosacea, acne or eczema inflammation, irritation from skincare, sun exposure, visible small vessels, a reaction to a procedure, infection and some medical conditions. The correct treatment depends on the cause rather than the colour alone.
Rosacea can include flushing, persistent central facial redness, burning or stinging, spots and eye symptoms. The NHS advises that it cannot be cured, but medical treatment can help control symptoms. An injectable skin treatment should not be presented as a replacement for diagnosis, prescribed rosacea care or assessment of new or changing redness.
What has been reported with polynucleotides?
A 2024 clinical letter described two patients who received three sessions of intradermal injections containing both polynucleotides and hyaluronic acid. Photographs taken four weeks after the third session appeared to show less redness across areas including the cheeks, chin and forehead.
This report is useful for generating a research question, but it is not a clinical trial. With only two people, no untreated or placebo comparison and no blinding, natural fluctuation, changes in triggers or skincare, photography and the effect of repeated needling cannot be separated from the injectable treatment.
The result cannot be attributed to polynucleotides alone
The injected formulation contained hyaluronic acid as well as polynucleotides. Even if the photographed change was genuine, the report cannot identify which component contributed or whether the combination mattered. It also cannot establish the best dose, number of sessions, duration of any change or which type of redness might respond.
Two authors disclosed advisory roles with the product manufacturer. This does not make the observation invalid, but it increases the importance of independent, controlled studies. A separate survey found that clinicians use polynucleotides for several causes of erythema, yet clinicians' impressions are not a substitute for measured comparative outcomes.
What broader evidence tells us
A 2026 systematic review found only seven randomised trials involving 183 participants across skin rejuvenation, scar prevention and wound healing. It reported encouraging findings but highlighted small samples, different products and protocols, and inconsistent outcome measures. Facial erythema was not established as a well-tested randomised indication.
It is therefore more accurate to say that polynucleotides for redness remain an emerging area of research. They should not be promised to close visible vessels, cure rosacea, stop flushing or reliably improve post-inflammatory redness. Depending on the diagnosis, gentle skincare, trigger management, medical treatment, a vascular procedure or no procedure may be more appropriate.
Downtime can temporarily look like more redness
Microinjections may cause short-term raised points, redness, swelling, tenderness, itching, pinpoint bleeding or bruising. When the original concern is redness, these normal early procedure effects may temporarily make the area look worse. Recovery varies, so treatment should not be scheduled immediately before an important event.
Less common problems include infection, persistent inflammation, lumps or an allergic reaction. Increasing pain, spreading heat or redness, discharge, fever, unusual skin colour or worsening swelling needs prompt clinical advice. Breathing difficulty or features of a severe allergic reaction require urgent medical help; eye pain or visual symptoms also need urgent assessment.
Individual assessment comes before an injectable
Consultation should ask when the redness started, whether it flushes or remains constant, possible triggers, burning, spots, visible vessels and eye symptoms. Active infection, an inflammatory flare or damaged skin may mean postponing treatment. Pregnancy or breastfeeding, allergies, medical conditions, medicines, previous reactions and other planned procedures must be reviewed for the exact product being considered.
GMC guidance requires doctors to explain evidence, risks, alternatives and follow-up without minimising uncertainty. For facial redness, a useful plan starts with a diagnosis and realistic goal, not a standard treatment course. Current evidence is too limited to predict who will benefit, how much change they may see or how long it might last.